Biological response modifiers
Authors:
- T. GamucciTGT. Gamucci
- 30 April 1995
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 12, S193-S198
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatinEuropean Journal of Cancer, 1993
- Chemotherapy-induced anemia in patients with primary lung cancerAnnals of Oncology, 1992
- Interleukin-2 and Interferon-α in the Treatment of Patients with Advanced Non-Small-Cell Lung CancerJournal of Immunotherapy, 1992
- Interleukin-2 with Ex Vivo Activated Killer Cells: Therapy of Advanced Non-Small-Cell Lung CancerJournal of Immunotherapy, 1991
- Original article: Potentiation of cisplatin by alpha-Interferon in advanced non-small cell lung cancer (NSCLC): A phase II studyAnnals of Oncology, 1990
- Recombinant interferon a (IFL-rA) therapy of small cell and squamous cell carcinoma of the lung. A phase II studyEuropean Journal of Cancer and Clinical Oncology, 1987
- Chemotherapeutic agents and the erythronCancer Treatment Reviews, 1983
- Cisplatin Toxicity for Erythroid PrecursorsNew England Journal of Medicine, 1981
- Cisplatin-Induced AnemiaNew England Journal of Medicine, 1980
- Preliminary clinical experience withcis-diamminedichloroplatinum (II) (NSC 119875, CACP)Cancer, 1972